Interview 20 Feb 2017 Investment CEO shares Tips for Academics on Succeeding in Business With decades of experience, the CEO of Touchstone Innovations tells us about funding the development of academic projects into commercialized products Formerly known as Imperial Innovations, the investing arm of Imperial College in London has since morphed into Touchstone Innovations, an UK technology commercialization and investment company with the same core mission in bridging the gap […] February 20, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2017 Microorganisms in the Library: Bringing Centuries-Old Books to Life Sarah Craske describes herself as a “British artist, without category.” Her work, at the intersection of art and science, revolves around the development of her own discipline: Biological Hermeneutics. Hermeneutics refers to the interpretation of texts, a term commonly used regarding the bible or philosophy. Craske translates the concept to biology by exploring the role […] February 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2017 Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials Arthrogen will start a Phase Ib trial for a gene therapy aiming to treat rheumatoid arthritis with a single injection and reduce costs for patients. Arthrogen, based in Amsterdam, is developing local gene therapies for inflammatory diseases. The biotech company has now announced it has received approval to start a Phase Ib trial with its lead […] February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2017 UPDATE: More Promising Results from Mologen’s New HIV Therapy Update (17/02/2017): Mologen has announced more positive data for lefitolimod in HIV, as the Danish Aarhus University Hospital showed for the first time that the drug can induce a local antiviral immune response in patients undergoing ART. Definitive results are expected later this year. Originally published on 11/01/2017 Mologen’s partner in the development of an HIV therapy has […] February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2017 UPDATE: British Biotech Investment Company goes Public with €117M UPDATE (17/02/2017): Arix Bioscience announced that it has successfully raised £100M (€117) in an oversubscribed IPO on the London Stock Exchange. Originally published on 02/02/2017 Arix Bioscience is getting ready for an IPO that could reach up to €117M (£100M). The funds will be directed at small life science companies. Arix Bioscience is a ‘global healthcare and life […] February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2017 British Scientists Discover how Deadly Bacteria Survive a Last-Line Antibiotic Researchers from the UK and Australia have described for the first time the detailed molecular mechanisms behind last-line antibiotic resistance. A month ago, the news of a woman who died of an infection with a bacteria resistant to all 26 antibiotics available in the US traveled the world. The bacterial strain responsible, Klebsiella pneumoniae, is one […] February 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2017 The Patent Office has Spoken: What does it Mean for CRISPR in Europe? The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […] February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 Actelion’s key Drug linked to Deaths, prompting EMA Investigation Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […] February 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech bids for Crowdfunding in Neurodegenerative Disease AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […] February 15, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech gets a Boost in the NASH Race with a Successful IPO Inventiva has completed an IPO on Euronext Paris raising €48M that will support the advancement of its pipeline, which includes big indications such as NASH. Inventiva, a drug discovery company from France, is the protagonist today of a successful biotech IPO on Euronext Paris despite the financial difficulties of past years. The company has raised €48M, which will […] February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 Optogenetics: What Makes It a Powerful Neuroscience Tool? It’s a brand-new field and possibilities seem infinite. Here’s what you need to know about its rapid development into a powerful genetic tool. What is Optogenetics? What if you could activate and deactivate neurons by simply switching on the lights? That’s the basis of optogenetics, the control of cell behavior via light-sensitive proteins. Optogenetics is a […] February 15, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Suffering from House Dust Mite Allergy? A New Therapy is on its Way Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […] February 14, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email